ACM
AGTC

Ativo Capital Management’s Applied Genetic Technologies Corporation AGTC Stock Holding History

Ativo Capital Management’s Portfolio AGTC Stock Details AGTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-86,019
Closed -$439K – 242
2017
Q2 		$439K Buy
+86,019
New +$483K 0.12% 212

Other funds holding AGTC

IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ativo Capital Management's AGTC Position: Q3 2017 in Review

Ativo Capital Management sold out of Applied Genetic Technologies Corporation (AGTC) in Q3 2017, closing a stake of 86,019 shares — an estimated $439K sold.

Ativo Capital Management first reported a position in AGTC in Q2 2017 and held it in 1 quarter. The position peaked at $439K in Q2 2017. 67 funds tracked by Wall St. Rank hold AGTC as of Q3 2017.

  • Ativo Capital Management reported no remaining Applied Genetic Technologies Corporation position as of Q3 2017 after selling out during the quarter.
  • Ativo Capital Management sold 86,019 Applied Genetic Technologies Corporation shares in Q3 2017, an estimated $439K.
  • Ativo Capital Management first reported a position in Applied Genetic Technologies Corporation in Q2 2017 and held it in 1 quarter.
  • Ativo Capital Management's Applied Genetic Technologies Corporation position peaked at $439K in Q2 2017.
  • 67 funds tracked by Wall St. Rank held Applied Genetic Technologies Corporation as of Q3 2017.

Based on Ativo Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.